NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant™

NeuroPace, Inc. (NASDAQ:NPCE) is one of the 10 Best Brain-Computer Interface Stocks to Buy.

On May 29, NeuroPace, Inc. (NASDAQ:NPCE) said it received U.S. Food and Drug Administration approval for ECoG Assistant, the first "AI-driven clinician-enabled feature." It is designed to help epilepsy care using long-term intracranial EEG data.

Built on 124,450 epileptologist-labeled records, the company reported that the tool has "ECoGs of Interest." It allows physicians to review trends and timing patterns across months through integrated reports and charts, improving efficiency in data review and treatment decisions.

Chief Medical Officer Martha Morrell said the feature "represents an important advancement," with faster access to insights for more informed care.

CEO Joel Becker said the approval shows how the firm's data advantage is moving toward "practical tools for clinicians."

NeuroPace, Inc. (NASDAQ:NPCE) debuted the technology at the ASSFN Annual Meeting on May 30. It has submitted its next-generation patient data platform for FDA review, targeting approval in the second quarter of 2026.

NeuroPace, Inc. (NASDAQ:NPCE) creates, produces, and markets implantable devices to treat

Fuente original: Yahoo Finance (https://finance.yahoo.com/healthcare/articles/neuropace-inc-npce-reveals-fda-153139132.html)